ERNA
Ernexa Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.37
−3.53%Aug 10, 2026, 13:01 UTC
Ernexa Therapeutics appointed David Polinsky, a veteran biotech executive, to its board of directors as the company approaches the clinical stage.
Source:Jul 15, 2026, 11:50 UTC
Ernexa Therapeutics receives independent validation of its drug ERNA-101 in ovarian cancer models, showing complete tumor clearance and durable survival, ahead of planned clinical entry.